利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

310 条记录 (耗时 0.043 秒)

    Death domain containing receptor 5
    1.
    发明申请
    Death domain containing receptor 5 审中-公开
    含有受体5的死亡域

    公开(公告)号：US20050233958A1

    公开(公告)日：2005-10-20

    申请号：US10979831

    申请日：2004-11-03

    申请人： Jian Ni ,  Reiner Gentz ,  Guo-Liang Yu ,  Craig Rosen

    发明人： Jian Ni ,  Reiner Gentz ,  Guo-Liang Yu ,  Craig Rosen

    IPC分类号： A61K38/00 ,  A61K38/17 ,  C07K14/705 ,  C07K16/28

    CPC分类号： C07K16/2878 ,  A61K38/00 ,  C07K14/70578 ,  C07K2317/622 ,  C07K2319/30

    摘要： The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and/or antagonists of DR5 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族的成员的新的含有死亡域的受体-5（DR5）蛋白，现在已经显示结合TRAIL。 特别地，提供编码人DR5蛋白的分离的核酸分子。 还提供了DR5多肽，载体，宿主细胞以及用于制备它们的重组方法。 本发明还涉及用于鉴定DR5活性的拮抗剂和拮抗剂的筛选方法。 本发明还涉及使用DR5特异性抗体（其可以是DR5活性的激动剂和/或拮抗剂）的减少或增加的细胞凋亡相关疾病的治疗。

    Polynucleotides encoding a human chemotactic cytokine I
    2.
    发明授权
    Polynucleotides encoding a human chemotactic cytokine I 失效
    编码人趋化因子I的多核苷酸

    公开(公告)号：US07393943B1

    公开(公告)日：2008-07-01

    申请号：US08761289

    申请日：1996-12-06

    申请人： Jian Ni ,  Guo-Liang Yu ,  Pedro Alfonso ,  Reiner Gentz ,  Jeffrey Y. Su

    发明人： Jian Ni ,  Guo-Liang Yu ,  Pedro Alfonso ,  Reiner Gentz ,  Jeffrey Y. Su

    IPC分类号： C07H21/04 ,  C12P21/06 ,  C12N1/20 ,  C12N15/00 ,  C12N5/00 ,  C12N5/02 ,  C12N15/74

    CPC分类号： C07K14/52 ,  C07H21/04

    摘要： Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.

    摘要翻译： 公开了人类趋化性细胞因子I多肽和编码这种趋化性细胞因子的DNA（RNA）以及通过重组技术产生此类多肽的方法。 还公开了利用这种趋化性细胞因子治疗白血病，肿瘤，慢性感染，自身免疫疾病，纤维化病症，伤口愈合和牛皮癣的方法。 还公开了抗这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎，自身免疫，慢性和急性炎性和感染性疾病，过敏反应，前列腺素不依赖性发烧和骨髓衰竭的治疗剂的用途。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码趋化性细胞因子的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定。

    Human endometrial specific steroid-binding factor I, II and III
    5.
    发明授权
    Human endometrial specific steroid-binding factor I, II and III 失效

    公开(公告)号：US06338948B1

    公开(公告)日：2002-01-15

    申请号：US09583169

    申请日：2000-05-30

    申请人： Jian Ni ,  Guo-Liang Yu ,  Reiner Gentz

    发明人： Jian Ni ,  Guo-Liang Yu ,  Reiner Gentz

    IPC分类号： C07K1618

    CPC分类号： C07K14/4702

    摘要： The invention relates to hESF I, II and III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

    Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta
    6.
    发明申请
    Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta 审中-公开
    肿瘤坏死因子受体6 Alpha＆6 Beta

    公开(公告)号：US20060234285A1

    公开(公告)日：2006-10-19

    申请号：US11419656

    申请日：2006-05-22

    申请人： Reiner Gentz ,  Guo-Liang Yu ,  Jian Ni ,  Reinhard Ebner ,  Ping Feng ,  Steven Ruben

    发明人： Reiner Gentz ,  Guo-Liang Yu ,  Jian Ni ,  Reinhard Ebner ,  Ping Feng ,  Steven Ruben

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  A61K38/17 ,  C07H21/04 ,  C12P21/06 ,  C07K14/715

    CPC分类号： G01N33/57488 ,  A61K38/00 ,  C07K14/70578 ,  C07K14/7151

    摘要： The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6α & -6β activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

    摘要翻译： 本发明涉及新型肿瘤坏死因子受体蛋白。 特别地，提供编码人TNFR-6α和-6β蛋白的分离的核酸分子。 还提供了TNFR-6α和-6β多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及鉴定TNFR-6α和-6β活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测免疫系统相关疾病的诊断方法和用于治疗免疫系统相关疾病的治疗方法。

    Chemotactic cytokine III
    7.
    发明申请
    Chemotactic cytokine III 审中-公开
    趋化性细胞因子III

    公开(公告)号：US20060073573A1

    公开(公告)日：2006-04-06

    申请号：US11244394

    申请日：2005-10-06

    申请人： Jian Ni ,  Reiner Gentz ,  Guo-Liang Yu ,  Jeffrey Su ,  Patrick Dillon

    发明人： Jian Ni ,  Reiner Gentz ,  Guo-Liang Yu ,  Jeffrey Su ,  Patrick Dillon

    IPC分类号： C12P21/02 ,  C07H21/04 ,  C07K14/52

    CPC分类号： C07K14/52 ,  A61K38/00 ,  C07K14/521 ,  Y02A50/423

    摘要： Human chemotactic cytokine III polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding chemotactic cytokine III and for detecting altered levels of the polypeptide in a host.

    摘要翻译： 公开了人类趋化性细胞因子III多肽和编码这种趋化性细胞因子的DNA（RNA）以及通过重组技术产生此类多肽的方法。 还公开了利用这种趋化性细胞因子治疗白血病，肿瘤，慢性感染，自身免疫疾病，纤维化病症，伤口愈合和牛皮癣的方法。 针对这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎，自身免疫和慢性和急性炎症和感染性疾病，过敏反应，前列腺素不依赖性发烧，脑缺血，肾小球肾炎，HTLV-1相关疾病和骨髓衰竭的治疗用途 也被披露。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码趋化性细胞因子III的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定。

    DNA encoding the chemotactic cytokine III
    9.
    发明授权
    DNA encoding the chemotactic cytokine III 失效
    编码趋化性细胞因子III的DNA

    公开(公告)号：US5952197A

    公开(公告)日：1999-09-14

    申请号：US812003

    申请日：1997-03-05

    申请人： Jian Ni ,  Reiner Gentz ,  Guo-Liang Yu ,  Jeffrey Su ,  Patrick J. Dillon

    发明人： Jian Ni ,  Reiner Gentz ,  Guo-Liang Yu ,  Jeffrey Su ,  Patrick J. Dillon

    IPC分类号： A61K38/00 ,  C07K14/52 ,  C12N15/19 ,  C12N15/00 ,  C12N15/63

    CPC分类号： C07K14/52 ,  C07K14/521 ,  A61K38/00

    摘要： Human chemotactic cytokine III polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding chemotactic cytokine III and for detecting altered levels of the polypeptide in a host.

    摘要翻译： 公开了人类趋化性细胞因子III多肽和编码这种趋化性细胞因子的DNA（RNA）以及通过重组技术产生此类多肽的方法。 还公开了利用这种趋化性细胞因子治疗白血病，肿瘤，慢性感染，自身免疫疾病，纤维化病症，伤口愈合和牛皮癣的方法。 针对这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎，自身免疫和慢性和急性炎症和感染性疾病，过敏反应，前列腺素不依赖性发烧，脑缺血，肾小球肾炎，HTLV-1相关疾病和骨髓衰竭的治疗用途 也被披露。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码趋化性细胞因子III的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定。